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Abstract
CLINICAL AND DEMOGRAPHIC CORRELATES OF DEPRESSSION IN STABLE HEART
FAILURE
In this secondary analysis of cross sectional data collected from 173 patients with chronic HF the
demographic, clinical, and sleep related factors present in patients with stable HF and major
depressive disorder (MDD) were explored. Participants were recruited from 5 structured HF
disease management programs in the Northeastern US. Measures include the Centers for
Epidemiological Studies Depression Scale (CESD), the Charlson Comorbidity Index (CCI), and
a sleep diary. Results indicate significant between group differences between patients with MDD
and without MDD in age, gender, NYHA, diabetes, chronic fatigue, asthma, past psychiatric
history, antidepressant use, anxiolytic use, insomnia, and taking sleeping pills. A logistic
regression incorporating age, gender, NYHA class, asthma, diabetes, and insomnia predicted
84.6% of patients with and without MDD, with insomnia remaining significant at a p = 0.002.
Major Depressive Disorder (MDD) is a common and under-diagnosed co-morbidity in stable
heart failure (HF), associated with worse outcomes and lower quality of life. Further
identification of the factors associated with MDD in patients with stable HF may help to improve
rates of diagnosis and treatment. Self reported insomnia was present in the majority of depressed
patients. Other characteristics of depressed patients in the sample include younger age, female
gender, NYHA class III/IV, and co-morbid asthma and diabetes.
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Introduction
Depression is common among the 5.8 million people who live with HF in the United States and
is associated with increased morbidity, mortality, healthcare costs, and decreased quality of life
(Hallas, Wray, Andreou, & Banner, 2011; Smith, 2010). Recent reviews suggest that rates of
depression among patients with HF range from 13-77%, although the wide range is likely due to
variability in the methods used to measure depression, definitions of depression as depressive
symptoms versus clinical depression, and whether or not patients were hospitalized at the time of
diagnosis (Delville & McDougall, 2008; Redeker, 2006). This compares with a prevalence of
Major Depressive Disorder (MDD) in 10%-25% of women and 5-12% of men in the general
population (APA, 2000). Depression is associated with poorer function, decreased quality of life,
increase in symptoms, increased mortality, and increased hospitalizations in patients with HF,
independent of severity of HF (Friedmann, et al., 2006; Hallas, et al, 2011; Lea, 2009; Sherwood,
et al., 2011; Ramasay, et al., 2006; Sullivan, Levy, Russo, & Spertus, 2004). Depression may
also be a risk factor for developing HF, particularly in high risk cardiac patients (Joynt, Whellan,
& O’Connor, 2004).
Patients with MDD are more likely to be classified as NYHA class III & IV, even when
these classifications cannot be explained by CV risk factors or lab work (Skotzko, 2009). The
overlap of symptoms and physiology between MDD and HF can lead to exacerbation of
symptoms, posing difficulties for both diagnosis and treatment. MDD also complicates
management of HF as it is linked to decreased compliance with HF treatment and low levels of
social support, both of which are associated with poor outcomes in HF, particularly in older
adults and patients with increased daytime sleepiness (Joynt et al, 2004; Luttik, Jaarsma, Moser,
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Sanderman, & van Veldhuisen, 2005; Maixner, Struble, Blazek, Kales, 2011; Riegel, et al.,
2011).
Although experts recommend screening all HF patients for MDD, especially those with
New York Heart Association Class III and IV HF (Skotzko, 2009; Lea, 2009; US Preventative
Task Force, 2009), depression remains under-diagnosed and under-treated in these patients. The
diagnosis of MDD is missed in approximately 16% of patients with HF in the primary care
setting (Delville and McDougall, 2008), and cardiologists inquire about depressive symptoms in
fewer than half of their patients (Feinstein, Blumenfield, Orlowski, Frishman, & Ovanssian,
2006). Under-diagnosis of MDD may be due to the shared pathophysiology of HF and MDD,
including increased catecholamine release, arrhythmias, elaboration of pro-inflammatory
cytokines and platelet activation (Joynt, Whellan, & O’Connor, 2004; Kupper, Widdershoven, &
Pedersen, 2011; Lea, 2009) that leads to an overlap in somatic symptoms, such as weight loss,
pain, distress, dyspnea, fatigue/anergy, disturbed sleep, cachexia, memory problems, and
functional decline (Skotzko, 2009). The stigma associated with mental illness may also be a
barrier to patient reports and provider questions about depression.
Effective diagnosis of MDD is important because the use of antidepressants as part of
pharmacologic treatment for depression may prevent cardiac deaths (Feinstein, et al; 2006).
Serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressants among
HF patients and can alleviate symptoms of both MDD and dyspnea, common in HF (Feinstein, et
al, 2006; Ramasamy, et al, 2006). Sertraline specifically improved quality of life in patients with
HF (Ramasamy et al, 2006). Unfortunately research on treatment options is limited, and some
evidence suggests that use of anti-depressants may be associated with adverse effects in HF
patients (Skotzko, 2009).
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The information on demographic characteristics associated with MDD in stable HF
patients is limited because many HF studies lack representation of women, young and middleaged adults, and minority group members (Bekelman, et al, 2007; Gottlieb, et al, 2004).
Depression may be more common in women than men, reflecting the trend in the general
population (Gottlieb, et al, 2004; Lea, 2009; Smith, 2010). Younger age (under 60) and living
alone are associated with depression in HF patients (Gottlieb, et al, 2004; Smith, 2010).
However, additional literature reflects no difference in rates of depression along race, gender, or
age in a study with primarily younger, Caucasian, heart transplant patients with HF (Sullivan,
Levy, Russo, & Spertus, 2004).
Self report of depression is associated with in an increase in the number of co-occurring
disorders in HF patients (Hayashino, et al, 2010). There is limited research on which diagnoses
are associated with MDD in stable HF patients, with the current literature focusing on
psychosocial factors and quality of life. Identifying readily available clinical information, such as
co-morbid conditions and symptoms, may assist providers in identifying patients most at risk for
having MDD and requiring focused screening and treatment.
Disturbances in sleep are widespread and highly incapacitating in MDD (Sbarra and
Allen, 2009). Likewise, sleep disturbance symptoms, such as insomnia, are important to the
diagnosis of depression in patients with stable HF (Redeker, 2006). However, the types of sleep
symptoms in patients with co-morbid MDD and HF remains poorly understood (Norra, et al,
2011; Wang, et al., 2009).
The purpose of this study is to describe the demographic and clinical characteristics and
symptoms of sleep disturbance associated with MDD in patients with stable HF. The following
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research questions were addressed: 1) What is the proportion of stable HF patients who have
MDD? 2)What is the proportion of patients with MDD who receive antidepressant medication?
3) What clinical (HF status, number or type of co-morbid conditions) and demographic (age,
gender, race) characteristics are associated with MDD in stable HF? 4) What characteristics of
sleep are associated with MDD in stable HF?
Methods
The study employed a cross-sectional observational design and consists of secondary analysis of
data obtained in a project designed to evaluate the contributions of sleep characteristics to
daytime symptoms and functional performance in patients recruited from five HF disease
management programs in the Northeastern U.S. Details of the overall study have previously
been reported, (Redeker, Jeon, et al., 2010a; Redeker, et al., 2010b), and are summarized here as
relevant to the current analysis. The study was approved by the institutional review board, and all
participants provided written informed consent.
Sample
The sample included 173 participants who had stable chronic heart failure (mean age =60.3±
16.8 years; n=60 [35%] female, n=50 [29%] African American; left ventricular ejection fraction
mean =32±14.6) (Redeker, et al, 2010a). Participants with stable HF were recruited through
referrals from providers at five HF disease management programs in the Northeastern U.S.
Eligibility criteria included the following: age > 18 years of age; stable HF (defined as no
hospital admissions within the previous month or adjustment of vaso-active medications within
the past 2 weeks); cognitively intact (assessed by clinical judgment). Subjects who were
pregnant, unstable medically or psychiatrically, or had ongoing alcohol or drug abuse were
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excluded. Subjects with a history of Parkinson’s disease, obstructive valvular, hypertrophic, or
surgically correctable valvular disease, renal failure, previously identified sleep disorders, and
hemiplegia affecting the non-dominant arm (confounding factor for actigraph monitoring) were
also excluded (Redeker, et al, 2010a).
Variables and Instruments
The Center for Epidemiological Studies Depression Scale (CESD) was used to measure
depressive symptoms. The CESD is a 20-item self report questionnaire. Participants respond to
each item according to their perceptions over the past week using a four point scale ranging from
a score of zero for rare (or none of the time) to three points for most (or all of time) (Mulhauser,
2011). Although a cut-off score of ≥16 indicates a likely diagnosis of MDD in the general
population (Bardwell, Ancoli-Israel, & Dimsdale, 2006), the presence of somatic symptoms in
HF suggests that a higher cut-off score would be more specific in cardiac patients (Contrada,
Boulifard, Idler, Krause, Labouvie, 2006). Therefore, we used a score of ≥ 28 as an indicator of
MDD (Zich, Attkisson, & Greenfield, 1990). The CESD has a high internal consistency of 0.87
and sufficient test-retest reliability and sensitivity/specificity (Redeker, et al, 2010a).
The Charlson Comorbidity Index (CCI) was used as a measure of comorbid conditions.
The CCI was originally developed for use in longitudinal studies to predict mortality based on
certain clinical conditions (Charlson, Pompei, Ales, & MacKenzie, 1987). Scores are weighted
based on severity of illness, and include conditions such as cardiac disease, diabetes, and cancer.
Demographic data, including age, gender, race, and living alone were obtained through
participant self-report and interview. Information on comorbid health problems and medications
was obtained through participant self-report and chart review. Information on sleep symptoms
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was obtained through self-report. Participants completed a sleep diary for three nights, reporting
specifics such as sleep latency, number of awakenings, and time of arousal. Sleep diaries are a
valid and reliable measure of insomnia commonly used in research (Epsie, 1991; Epsie, Inglis,
Tessier, & Harvey, 2001).
Procedures
A research assistant (RA) recruited participants at participating sites during a routine visit to their
HF program. The assistant explained the study, obtained informed consent, and reviewed
medical records. Following the initial contact participants completed a packet of questionnaires
addressing symptoms, depression and quality of life. Only the data on demographics, the CESD,
the CCI, sleep symptoms, and co-occurring diagnoses are reported here. For the larger study,
participants also completed one night of polysomnography in their homes and 3 days of wrist
actigraphy. Upon completion of data collection each participant received $50. (Redeker, et al,
2010a; Redeker, et al, 2010b)
Data Analysis
All data were entered into a database. Full details of this approach have previously been
described (Redeker, et al, 2010a). SPSS version 18 was used to compute descriptive statistics
and to compare the categorical and continuous variables (chi-square, dependent groups t-test) on
MDD. Covariance among clinical, demographic, and sleep variables was conducted using a
logistic regression. Clinical and demographic variables included in the regression analysis were
selected based on their significant bivariate associations with MDD.
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Results
Demographic
Of the 324 patients initially approached, 41 were ineligible, 233 consented, and complete data
were obtained for 173 participants. The overall sample included 60 females (34.7%) and 61
minority participants (35.7%). Full details of racial breakdown of participants in the minority
group were previously reported, and are combined here for ease. The average left ventricular
ejection fraction is 32.6, NYHA class is 2.5, body mass index 30.7. (Redeker, et al, 2010a)
The overall group CESD score was (M = 16.98 + 11.01, range of 0-54). Table 1 lists the
demographic and clinical characteristics of participants with and without MDD, based on a
cutoff score of ≥ 28.
Younger and female participants were significantly more likely to have MDD. There
were no statistically significant differences in depression based on race or living alone.
Clinical
There were statistically significant differences between participants with and without MDD on
NYHA class, with 59.4% of those with MDD having NYHA class III or IV, but there were no
statistically significant differences in LVEF. There were no statistically significant differences
between those with and without MDD on the Charlson Comorbidity Index, but diabetes (MDD
46.9%, no MDD 24.8%), rheumatoid Arthritis (MDD 21.9%, no MDD 9.3%, p = 0.051), chronic
fatigue (MDD 18.8%, no MDD 5.7%), asthma (MDD 25%, no MDD 10%), and a past history of
psychiatric disorders (MDD 47%, no MDD 3.6%) were significantly more common in patients
with MDD. There were no statistically significant differences between groups with and without
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MDD on the proportion of patients who had thyroid disease, anemia, osteoarthritis, cancer,
COPD, GI disorders, or urinary tract disorders.
Patients with MDD were significantly more likely to be on antidepressants (MDD 33.3%,
no MDD 10.7%), anxiolytics (MDD 33.3%, no MDD 4.3%), sedative hypnotics (MDD 13.3%,
no MDD 4.3%), and insulin. The most common class of antidepressants was SSRIs (58.7%
total). Benzodiazepines were prescribed 81.3% of the time, and Ambien was prescribed 85.7% of
the time as a sedative hypnotic.
Sleep Symptoms
There were statistically significant differences between groups with and without MDD on sleep
symptoms , including trouble falling asleep (MDD 64.5%, no MDD 44%), difficulty resuming
sleep (MDD 58.1%, no MDD 34.8%), waking too early (MDD 58.1%, 29.8%), not feeling rested
during the day (MDD 80.6%, no MDD 44.7%), feeling overly sleepy during the day (MDD
67.7%, no MDD 37.6%), and not getting enough sleep (MDD 67.7%, no MDD 42.6%).
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Table 1
Comparison of participants with and without clinical depression (MDD) based on score of ≥28 indicating
MDD on demographic and clinical variables

Demographic Variables
Age (mean in years)
Gender*

No MDD
(N=141 /81.5%)

MDD
(N=32/18.5%)

M (SD)/N (%)

M (SD)/N (%)

61.44 (16.38)

55.53(23.84

Male
Female

98(69.5%)
43 (30.5%)

15(45.9%)
17(53.1%)

White
Minority

91 (65.0%)
49 (35.0%)
26 (18.4%)

19 (61.3%)
12 (38.7%)
7 (21.9%)

87 (61.7%)
54 (38.3%)
30.5 (7.91)
2.4 (1.51)
35 (24.8%)
22 (15.8%)
26 (18.6%)
13 (9.3%)
21 (15.0%)
18 (12.9%)
8 (5.7%)
14 (10.0%)
14 (10.0%)
32 (23.2%)
23 (16.4%)
22(15.9%)
15(10.7%)

13 (40.6%)
19 (59.4%)
31.7 (8.66)
2.65 (1.60)
15 (46.9%)
5 (15.6%)
9 (28.1%)
7 (21.9%)
7 (21.9%)
3 (9.4%)
6 (18.8%)
8 (25.0%)
6 (19.4%)
11 (35.5%)
4 (12.5%)
15(46.9%)
10(33.3%)

60 (43.2%)
62 (44.0%)
49 (34.8%)
42 (29.8%)
63 (44.7%)

26 (83.9%)
20 (64.5%)
18 (58.1%)
18 (58.1%)
25 (80.6%)

Race

Living Alone
Clinical Variables
Left ventricular ejection fraction (5)
NYHA classification*:
Class I, II
Class III, IV
Body Mass Index (mean)
Charlson Comorbidy Index (mean)
Diabetes*
Thyroid Disease
Anemia
Rheumatoid Arthritis
Osteoarthritis
Cancer
Chronic Fatigue*
Asthma*
COPD
GI
Renal
Psychiatric***
Antidepressant Use***
Sleep Variables
Difficulty Initiating and Maintaining sleep***
Trouble falling asleep*
Difficulty Resuming Sleep*
Waking too early**
Unrested during day**
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Overly sleepy**
53 (37.6%)
21 (67.7%)
Not enough sleep*
60 (42.6%)
21 (67.7%)
Taking sleeping pills**
13 (9.2%)
10 (32.3%)
Comparisons for categorical variables used chi-square; comparisons for continuous variables used
dependent group t-tests.***P < 0.001, **P < 0.01, * P < 0.05

Logistic Regression
A logistic regression using age (<61), gender (female), NYHA class (III/IV), asthma, diabetes,
and insomnia, was run with 84.6% prediction for patients with and without MDD. Using this
model we were able to correctly identify 38.7% of depressed patients, and 95% of non-depressed
participants. When all six variables were included, age, gender, diabetes, and insomnia remained
significant (p ≤ 0.05). Insomnia remained the most significant, with a p = 0.002. There was no
statistically significant finding for NYHA or asthma in the multivariate model. Younger patients
and patients with diabetes had almost three times the odds of having MDD, women and patients
with NYHA class III/IV 2.5 times the odds, and patients with asthma had 1.7 times the odds.
Insomnia increased the odds of MDD 5.5 fold.
Table 2
Logistic Regression of the Associations Among Clinical and
Demographic Characteristics, Insomnia Symptoms and MDD
OR
Variables
Age
Gender
NYHA
Diabetes
Asthma
Insomnia

CI (95)

2.91 1.14-1.46
2.53 1.00-6.38
2.48
.99-6.23
2.89 1.12-7.46
1.69
.52-5.53
5.42 1.88-15.61

P-value
0.026
0.049
0.053
0.028
0.379
0.002
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Discussion
The rates of MDD in this sample (19%) were lower than reported symptoms of
depression, but were consistent with reports of clinically significant depression in this population
(Lea, 2009). While symptoms of depression are more common and problematic in patients with
stable HF, the distinction of patients with clinical depression is important. Patients meeting DSM
–IV criteria for MDD may be at more risk for complications with their HF and would benefit
from treatment for their MDD. Our study extends previous work by including a larger proportion
of women and minority patients, and includes participants who were selected because they had
stable HF rather than hospitalized patients with acute HF who are often the focus of the literature
(Norra, et al, 2011). Hospitalized patients are likely to have higher levels of MDD and insomnia
due to the acuity of their illness and their environment, and may require different evaluation and
management of symptoms than stable outpatients.
Unlike many past studies that included few women and either did not report the
proportion of minority patients or included few minorities, the current study was more
representative of the general population of HF patients. Therefore the results may be more
generalizable to typical practice settings. Given that we found no significant differences in rates
of MDD in minority patients, in contrast to previous literature (Sullivan, et al., 2004), further
research is needed on the relationship between MDD and race.
The higher rate of MDD in younger and female patients is consistent with the literature
(Lea, 2009). This is reflective of higher rates of MDD in females in the general population,
though it is unclear whether MDD is more common in females or if men are less likely to report
mood symptoms. The higher rates of MDD in younger HF patients may be associated with the
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difficulty of living with a disabling illness at a younger age. We found no significant association
between living alone and MDD, which had previously been reported as an independent predictor
for the development of symptoms of depression (Lea, 2009).
The clinical characteristics significantly related to MDD in this sample were NYHA class
III/IV, insomnia, diabetes, rheumatoid arthritis, chronic fatigue, asthma, and past psychiatric
history. Interestingly the number of comorbid conditions was not significantly related to MDD.
Nearly half (47%) of patients with MDD had a psychiatric history, though only 33% of patients
with MDD were prescribed antidepressants. This is significant in that more than half of patients
with MDD do not have a previous history of psychiatric illness, and many patients in treatment
still have symptoms significant enough to meet criteria for MDD. While we did not specify
diagnoses for psychiatric history, our results indicate that a large number of patients with MDD
were under treated. Almost half of the patients in this sample with diabetes scored as clinically
depressed, indicating that rates of MDD are significantly higher among patients with diabetes
and HF. These findings expand on previous research indicating an association between MDD
and the number of comorbid conditions (Hayashino, Yamazaki, Takegami, Nakayama, &
Sokejima, 2010).
The sample resembled previous research samples as there were high rates of insomnia
(51%), with past studies reporting insomnia in 33-64% of HF patients (Redeker, et al, 2010a;
Brostrom & Johansson, 2005; Wang, et al, 2010). The significant rate of insomnia in patients
with MDD has implications for treatment. While insomnia and hypersomnia are symptoms of
MDD (APA, 2000), insomnia may be a risk factor for developing MDD, and treating insomnia
or MDD without treating the other will lead to a relapse of both disorders (Sateia, 2009).
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The most significant sleep symptom was feeling unrested during the day, with 80.6% of
depressed patients reporting daytime fatigue. All three symptoms of insomnia, difficulty
initiating and maintaining sleep, and waking too early in the morning, were significantly
associated with MDD. Fatigue and sleeping difficulties, along with poor appetite, have
previously been described as the depressive symptoms most predictive of cardiovascular events
(Hoen, et al., 2010). A thorough evaluation of sleep symptoms and insomnia may help providers
identify patients most likely to have MDD.
The six classes of medications most related to MDD were antidepressants, anxiolytics,
insulin, sedative hypnotics, and a self report of taking sleeping pills (other than sedative
hypnotics). The use of antidepressants and anxiolytics may be related to the high prevalence of
MDD among patients with a past psychiatric history. Anxiety and MDD are related disorders and
are often found together in clinical practice. First line treatment for both disorders is an SSRI.
Though for many patients, use of an antidepressant alone may not alleviate symptoms of
depression. The high rates of MDD among patients already on an antidepressant may indicate
that these are patients requiring titration of their psychiatric medications, or perhaps patients with
refractory depression who would benefit from medication management in a psychiatric setting.
The high rate of MDD among patients with diabetes may explain the association between insulin
and MDD. The use of sleep aids indicates difficultly sleeping, which is highly correlated with
MDD in this population.
Initially in our analysis we looked at the number of diagnoses (CCI) but found no
significant between group differences for MDD and no MDD. We then conducted a multivariate
analysis to look at the combined effect of the various individual characteristics with significant
between group differences. Since many patients with stable HF have multiple diagnoses, the
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combined regression allowed us to see how those factors affect each other. The multivariate
analysis indicates that patients with insomnia have five-fold odds of having MDD; however, age,
diabetes, and gender are also significantly associated with MDD. Surprisingly, unlike previous
studies, we did not find that NYHA class was associated with MDD in these multivariate
analyses. Whether these factors are causative of MDD or a result of MDD patients remains
poorly understood. Additional research is needed to further explore their interaction.
Limitations of the study include not screening for anxiety, as the initial study was
investigating sleep, not depression. Additionally, we obtained limited information on psychiatric
symptoms, history, and treatment. Diagnosis of MDD was not obtained by interview evaluating
DSM-IV criteria; rather we selected a measure we thought would closely approximate clinical
diagnosis. We also did not assess for functionality related to MDD. As this is a secondary
analysis, information regarding anxiety symptoms, titration status of medications, and past
medication trials, was not obtained. The cross sectional design has limitations in predicting and
accounting for changes over time.
Clinical Implications
Despite recommendations to screen all HF patients for depression, time and other factors often
do not allow for that screening to occur on a regular basis. Identifying readily available clinical
factors that increase the odds of having MDD may help address this concern. Clinicians may
benefit from knowing younger female patients with insomnia are most at risk for having MDD
and can then conduct more focused screenings. The finding that insomnia symptoms were
present in a large majority (83.9%) of depressed patients suggests that querying patients about
insomnia symptoms may be a non-intrusive way of identifying patients with depression. HF
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patients may feel more comfortable reporting sleep symptoms than depressive symptoms, and
those reports may be indicative of depression. Patients reporting sleep symptoms should be
evaluated for depression. One third of patients with MDD were on antidepressants, indicating
that while initiating an antidepressant is a first step, medications must be titrated until clinical
efficacy is obtained. Evaluation of depression should occur frequently to determine efficacy of
treatment and need for additional dosages increases or switching to another agent.
Research Implications
Further research is needed on treatment options for MDD and insomnia in this population.
Additional research is needed to explore the associations between inflammatory medical
conditions and MDD in HF patients, particularly implications for management. Future research
may also evaluate the difference in effect of MDD and depressive symptoms on HF, and at what
point treatment is indicated.
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